Search results
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoMinerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript March 8, 2023 Operator:...
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?
Zacks via Yahoo Finance· 3 weeks agoMinerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism...
Minerva Neurosciences Shares Sink On Regulatory Setback For Schizophrenia Candidate
Benzinga via Yahoo Finance· 2 years agoMinerva Neurosciences Inc (NASDAQ: NERV) has received a refusal to file letter from the FDA...
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up
Zacks via Yahoo Finance· 2 years agoMinerva Neurosciences NERV submitted a new drug application (“NDA”) to the FDA seeking approval of...
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Zacks via Yahoo Finance· 1 year agoMinerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking...
Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
Simply Wall St. via Yahoo Finance· 2 years agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher
Zacks via Yahoo Finance· 2 years agoMinerva Neurosciences (NERV) appears to have found support after losing some value lately, as...
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
Zacks via Yahoo Finance· 2 years agoIt was a busy week for the volatile biotech sector, with important regulatory and pipeline updates...
Minerva schizophrenia drug rejected by FDA
BioPharma Dive via Yahoo Finance· 3 months agoDive Brief: The Food and Drug Administration has rejected an experimental schizophrenia drug from Minerva Neurosciences, denying the biotechnology...
Minerva Neurosciences: Q4 Earnings Snapshot
Associated Press Finance via Yahoo Finance· 3 months agoBURLINGTON, Mass. (AP) — BURLINGTON, Mass. (AP) — Minerva Neurosciences Inc. (NERV) on Thursday reported a loss of $9 million in its fourth quarter. The Burlington, Massachusetts-based company ...
